Pfizer Engages with U.S. Government on Drug Pricing Policy Discussions
Pfizer and other pharmaceutical firms have discussed most-favored-nation drug pricing with the U.S. government, highlighting potential impacts on insurance and payer strategies.
Inflation Reduction Act Expected to Lower Medicare Part D Out-of-Pocket Costs for Specialty Drugs
New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.
Medicare Inflation Rebates: Extending Protections to Medicare Advantage Enrollees
Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.
U.S. Pushes ‘Most Favored Nation’ Drug Pricing Policy Amid Legal and Industry Challenges
The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.
U.S. Takes Steps to Lower Drug Prices Through Executive Order and Medicare Negotiations
President Trump's executive order and CMS initiatives mark significant moves to reduce drug prices through broadened Medicare price negotiations including Part B drugs, impacting pharmaceutical industry dynamics and regulatory compliance.
CMS Narrows Medicare Drug Price Negotiation Timeline for Hyluronidase-Enhanced Biologics
CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.
Trump Orders 30-Day Deadline for Drugmakers to Lower U.S. Prescription Prices
President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.
Trump Executive Order to Cut U.S. Prescription Drug Prices 30-80%
President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.
Trump Administration to Reintroduce 'Most Favored Nation' Drug Pricing for Medicare
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
Pharma Firms Boost Consumer Drug Ads Amid Tax Benefits Concerns
Pharmaceutical companies increased consumer-directed drug advertising by nearly 30% in early 2025, leveraging tax deductions that affect prescription drug prices, according to AHIP and CSRxP analyses.